Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

487
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
487
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

494
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
494
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

419
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
419
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

534
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
534

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Phantom Limb Pain Following Amputation in Pediatrics.

American journal of physical medicine & rehabilitation·2026
Same author

Unravelling the fungal endomicrobiome of Picrorhiza kurrooa for increasing in-planta picroside biosynthesis using endophytic Trichoderma harzianum PKRF1.

Environmental microbiome·2026
Same author

Comparative Evaluation of Microbial Counts in GCF of Patients with Onlay- Retained Fixed Partial Denture Fabricated with Monolithic Zirconia and DMLS - An <i>Ex vivo</i> Study.

Journal of pharmacy & bioallied sciences·2026
Same author

Cyanoacrylate polymeric films with the potential to be used as medicinal glues.

Annales pharmaceutiques francaises·2026
Same author

Precision pharmaceutics: bioinformatics and pharmacogenomics as catalysts for personalized drug therapy.

The Journal of pharmacy and pharmacology·2026
Same author

Gallic- and ω-3-linolenic-acids-mediated MgO nanoplates enable band-edge tuning and ROS-driven anticancer activity.

Colloids and surfaces. B, Biointerfaces·2026

Related Experiment Video

Updated: Feb 18, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K

Kidney Cancer: Current Progress in Treatment.

Ankita Thakur1, Sunil K Jain1

  • 1Faculty of Pharmacy, Adina Institute of Pharmaceutical Sciences, Sagar, M.P. - 470002, India.

World Journal of Oncology
|November 18, 2017
PubMed
Summary

Kidney cancer, primarily renal cell carcinoma, is increasing globally. New targeted therapies and immunotherapies offer survival benefits for select patients with advanced disease.

Keywords:
ImmunotherapyKidney cancerNephrectomySorafenibSunitinib

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.8K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

Related Experiment Videos

Last Updated: Feb 18, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.3K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.8K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

Area of Science:

  • Oncology
  • Nephrology
  • Cancer Biology

Background:

  • Kidney cancer represents 2% of global cancer diagnoses, with rising incidence and mortality.
  • Renal cell carcinoma (RCC) is the predominant histological subtype.
  • Key risk factors include smoking, obesity, and genetic predispositions.

Purpose of the Study:

  • To review current understanding of kidney cancer epidemiology and risk factors.
  • To summarize advancements in targeted therapies and immunotherapies for metastatic RCC.
  • To highlight emerging molecular pathways and treatment strategies.

Main Methods:

  • Review of epidemiological data on kidney cancer incidence and mortality.
  • Analysis of clinical trial outcomes for novel therapeutic agents in metastatic RCC.
  • Exploration of molecular pathways implicated in RCC pathogenesis.

Main Results:

  • Immunotherapy provides a survival advantage in a subset of metastatic RCC patients (approx. 20%) with specific predictive markers.
  • Small molecule inhibitors (sunitinib, sorafenib, temsirolimus) and monoclonal antibodies (bevacizumab) demonstrate anti-tumor activity.
  • These agents have become standard of care for many patients with advanced RCC.

Conclusions:

  • Targeted therapies and immunotherapies represent significant progress in managing advanced kidney cancer.
  • Further research into molecular pathways may identify new therapeutic targets.
  • Personalized treatment approaches based on predictive characteristics are crucial for optimizing outcomes in RCC.